{"id":"treatment-h","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":{"setId":"a8a2b3c1-ecda-4fc9-b3fd-bb94cfee6e80","title":"HAIR REGROWTH TREATMENT (MINOXIDIL) AEROSOL, FOAM [MEIJER DISTRIBUTION INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without a brand name or additional identifying information, 'Treatment H' cannot be matched to a specific marketed pharmaceutical product. This appears to be either a placeholder designation, an internal code name, or a non-existent drug.","oneSentence":"Treatment H is not a recognized or publicly documented AstraZeneca drug product.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:49:32.393Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03856229","phase":"NA","title":"Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS","status":"ENROLLING_BY_INVITATION","sponsor":"Centro de Investigación en. Enfermedades Infecciosas, Mexico","startDate":"2019-03-04","conditions":"Pneumocystis, HIV/AIDS, Steroid","enrollment":196},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT07072468","phase":"PHASE2","title":"Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)","status":"RECRUITING","sponsor":"VM Therapeutics LLC","startDate":"2025-12-12","conditions":"Chemotherapy-induced Peripheral Neuropathy, Drug-Induced Nephropathy","enrollment":16},{"nctId":"NCT06948448","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-11-18","conditions":"Colorectal Cancer","enrollment":144},{"nctId":"NCT04019002","phase":"PHASE1","title":"Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma","status":"COMPLETED","sponsor":"Susan Chang","startDate":"2019-11-19","conditions":"Glioblastoma Multiforme (GBM)","enrollment":17},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT07327970","phase":"","title":"Prospective Validation of Ataraxis AI Test for Predicting Treatment Response in Neoadjuvant Breast Cancer","status":"RECRUITING","sponsor":"Young-Joon Kang","startDate":"2026-01-20","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":120},{"nctId":"NCT03783000","phase":"PHASE1","title":"A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-01-15","conditions":"Healthy","enrollment":6},{"nctId":"NCT04167969","phase":"PHASE1","title":"The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-17","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT04164199","phase":"PHASE3","title":"Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2019-12-19","conditions":"Advanced Malignancies","enrollment":404},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT04751175","phase":"PHASE4","title":"Management of Pain in Lumbar Arthrodesis","status":"COMPLETED","sponsor":"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","startDate":"2013-07-04","conditions":"Pain, Postoperative","enrollment":128},{"nctId":"NCT04751370","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-08","conditions":"Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":31},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT06778122","phase":"NA","title":"In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors","status":"RECRUITING","sponsor":"University College, London","startDate":"2026-01-23","conditions":"Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs","enrollment":10},{"nctId":"NCT03654170","phase":"PHASE1","title":"A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-09-11","conditions":"Healthy","enrollment":6},{"nctId":"NCT06507904","phase":"PHASE1","title":"A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-09-15","conditions":"Healthy","enrollment":52},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT07498855","phase":"","title":"Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-10-01","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT06991738","phase":"PHASE1, PHASE2","title":"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Thyroid Cancer","enrollment":18},{"nctId":"NCT04439292","phase":"PHASE2","title":"Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":35},{"nctId":"NCT05556824","phase":"PHASE2","title":"Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Microbiome Health Sciences","startDate":"2023-03-03","conditions":"Gastroesophageal Reflux","enrollment":247},{"nctId":"NCT04266665","phase":"PHASE4","title":"Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome","status":"COMPLETED","sponsor":"Georgia Tsaousi","startDate":"2020-03-12","conditions":"Brain Tumor, Metabolic Disturbance, Inflammatory Response","enrollment":56},{"nctId":"NCT04891198","phase":"PHASE2","title":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2021-08-06","conditions":"Solid Tumor","enrollment":126},{"nctId":"NCT07326800","phase":"NA","title":"Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) in Breast Cancer Patients Undergoing Chemotherapy","status":"RECRUITING","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2026-02-16","conditions":"Non Metastatic Breast Cancer, Chemotherapy","enrollment":190},{"nctId":"NCT06561711","phase":"PHASE4","title":"Optimization of Minocycline for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":"Helicobacter Pylori Infection","enrollment":480},{"nctId":"NCT07492615","phase":"PHASE2","title":"A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-29","conditions":"Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":276},{"nctId":"NCT06977841","phase":"NA","title":"Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2025-06-10","conditions":"Helicobacter Pylori Eradication, Adverse Reaction","enrollment":640},{"nctId":"NCT07223021","phase":"PHASE3","title":"A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-20","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":130},{"nctId":"NCT06323460","phase":"PHASE2","title":"Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-03-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT06863402","phase":"PHASE2","title":"Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Richter Syndrome, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia","enrollment":32},{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":"Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer","enrollment":480},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT04990323","phase":"PHASE1, PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":"High Risk Myeloid Malignancies, Cord Blood Transplant","enrollment":13},{"nctId":"NCT07487142","phase":"PHASE3","title":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-10","conditions":"H Pylori Infection","enrollment":121},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT04316117","phase":"PHASE2","title":"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-09-15","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":138},{"nctId":"NCT07488663","phase":"NA","title":"MODELING OBSESSIVE COMPULSIVE DISORDER AND EXPLORING TREATMENT RESPONSE USING INNOVATIVE THERAPIES AND STEM CELLS","status":"ENROLLING_BY_INVITATION","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2023-04-30","conditions":"Obsessive - Compulsive Disorder","enrollment":60},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma","enrollment":252},{"nctId":"NCT03049072","phase":"","title":"Ion Therapy Patient Registry","status":"RECRUITING","sponsor":"EBG MedAustron GmbH","startDate":"2016-12","conditions":"Ion Beam Radiation Therapy for Tumor Patients","enrollment":2800},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT07487909","phase":"PHASE1, PHASE2","title":"A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol","status":"COMPLETED","sponsor":"Sen-Jam Pharmaceutical","startDate":"2025-09-30","conditions":"Healthy","enrollment":47},{"nctId":"NCT07488299","phase":"NA","title":"The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial.","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2026-03-20","conditions":"Pancreatic Walled-off Necrosis","enrollment":120},{"nctId":"NCT07328958","phase":"NA","title":"Effect of Titrated Administration of Ciprofol on Perioperative Hypotension in Elderly Patients Undergoing Laparoscopic Abdominal Surgery: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-01-16","conditions":"Hypotension During Surgery","enrollment":500},{"nctId":"NCT03164460","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer","status":"SUSPENDED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-05-22","conditions":"Recurrent Head and Neck Carcinoma","enrollment":68},{"nctId":"NCT07484139","phase":"PHASE2","title":"H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-05","conditions":"Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT05191940","phase":"NA","title":"Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)","status":"RECRUITING","sponsor":"EBG MedAustron GmbH","startDate":"2022-05-16","conditions":"Pancreas Cancer","enrollment":30},{"nctId":"NCT04894643","phase":"NA","title":"Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"EBG MedAustron GmbH","startDate":"2020-09-14","conditions":"Pancreatic Cancer, Proton Therapy","enrollment":10},{"nctId":"NCT05661955","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-09","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma","enrollment":113},{"nctId":"NCT05359211","phase":"PHASE1","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-08","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT06898450","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Nimbus Wadjet, Inc.","startDate":"2025-03-31","conditions":"Advanced Solid Tumors Cancer, MSI-H Cancer","enrollment":134},{"nctId":"NCT06133062","phase":"PHASE2","title":"Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-11-16","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":45},{"nctId":"NCT03281889","phase":"NA","title":"Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-01-04","conditions":"Brain Tumor","enrollment":20},{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT07398677","phase":"NA","title":"SchoolCare: A Social Intervention Introducing Telepresence Robots and School Navigation to Reduce School Fragmentation for Children Undergoing Cancer Treatment","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-02-20","conditions":"School Attendance, Academic Level, Childhood Cancer Survivors","enrollment":128},{"nctId":"NCT07403721","phase":"PHASE1","title":"AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors","status":"RECRUITING","sponsor":"Amgen","startDate":"2026-03-23","conditions":"Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)","enrollment":464},{"nctId":"NCT03737994","phase":"PHASE2","title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-25","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":10},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT07183267","phase":"NA","title":"Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Years Old, Receiving Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2026-06-01","conditions":"Radio Dermatitis, Mucositis Oral, Oesophagitis","enrollment":248},{"nctId":"NCT07478588","phase":"NA","title":"Structured Physical Activity Intervention in Patients With MASLD Receiving a Mediterranean Diet","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-06-01","conditions":"MASLD","enrollment":96},{"nctId":"NCT03276832","phase":"EARLY_PHASE1","title":"Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-12-20","conditions":"Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7","enrollment":7},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT02918214","phase":"","title":"Prognostic Assessment of Diastolic and Systolic Left Ventricular Function in Septic Shock","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2017-01","conditions":"Septic Shock, Echocardiography, Diastolic Dysfunction","enrollment":440},{"nctId":"NCT07483346","phase":"PHASE1","title":"IASO-782 in Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Shanghai IASO Biotechnology Co., Ltd","startDate":"2026-04-30","conditions":"SLE - Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT01659203","phase":"PHASE1, PHASE2","title":"Proton or Photon RT for Retroperitoneal Sarcomas","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2012-12","conditions":"Retroperitoneal Sarcoma","enrollment":80},{"nctId":"NCT05799105","phase":"PHASE4","title":"OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers","status":"RECRUITING","sponsor":"Stephen Firkins","startDate":"2023-03-14","conditions":"Marginal Ulcer","enrollment":122},{"nctId":"NCT05998902","phase":"PHASE3","title":"Optimizing Early Nutrition Support in Severe Stroke-2","status":"RECRUITING","sponsor":"Wen Jiang-3","startDate":"2023-12-20","conditions":"Severe Stroke, Acute Stroke, Dysphagia","enrollment":546},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT07479745","phase":"PHASE1","title":"Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019","status":"NOT_YET_RECRUITING","sponsor":"Grünenthal GmbH","startDate":"2026-03-26","conditions":"Healthy Male Volunteers","enrollment":10},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05538208","phase":"PHASE2","title":"The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-06-07","conditions":"Lupus Nephritis","enrollment":105},{"nctId":"NCT06324357","phase":"PHASE1, PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":"Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":768},{"nctId":"NCT03057756","phase":"","title":"Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2015-09-11","conditions":"Multi-drug Resistant Tuberculosis","enrollment":23},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT07476846","phase":"NA","title":"rhTPO Dose Escalation vs Eltrombopag Switch in ITP","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":112},{"nctId":"NCT07478224","phase":"NA","title":"An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life in Adults With Osteogenesis Imperfecta Type I","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-08-19","conditions":"Osteogenesis Imperfecta, Type I","enrollment":40},{"nctId":"NCT06205836","phase":"PHASE2","title":"Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-06-13","conditions":"Colorectal Cancer","enrollment":44},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT06649331","phase":"PHASE2","title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-21","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":160},{"nctId":"NCT07361302","phase":"PHASE3","title":"A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-02-17","conditions":"Acute Ischemic Stroke","enrollment":1325},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT04732065","phase":"PHASE1","title":"ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors","status":"RECRUITING","sponsor":"Sabine Mueller, MD, PhD","startDate":"2021-08-23","conditions":"Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma","enrollment":208},{"nctId":"NCT04190446","phase":"PHASE2","title":"A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-01-06","conditions":"Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":84},{"nctId":"NCT06483048","phase":"PHASE1","title":"MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-09-20","conditions":"Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":12},{"nctId":"NCT06116136","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Servier Bio-Innovation LLC","startDate":"2024-08-31","conditions":"MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer","enrollment":48},{"nctId":"NCT06508463","phase":"PHASE1","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":"Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified","enrollment":21},{"nctId":"NCT07130682","phase":"NA","title":"Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial","status":"RECRUITING","sponsor":"Hong Kong Sanatorium & Hospital","startDate":"2025-09-01","conditions":"Prostate Cancer Patients Treated by Radiotherapy","enrollment":35},{"nctId":"NCT07245745","phase":"NA","title":"Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer","status":"RECRUITING","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2026-01-13","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT06186401","phase":"PHASE1","title":"Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells","status":"RECRUITING","sponsor":"Hideho Okada, MD, PhD","startDate":"2024-04-30","conditions":"EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma","enrollment":20},{"nctId":"NCT06861010","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-03-01","conditions":"Pancreatic Diseases","enrollment":44},{"nctId":"NCT06288113","phase":"PHASE2","title":"Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":40},{"nctId":"NCT06784726","phase":"PHASE2","title":"Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-09-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT05033288","phase":"","title":"Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-01-20","conditions":"Bone Sarcoma, Chondrosarcoma, Chordoma","enrollment":72},{"nctId":"NCT06442475","phase":"PHASE2","title":"Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-08-29","conditions":"Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma","enrollment":20},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":274,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Treatment H","genericName":"Treatment H","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Treatment H involves the use of L-Carnitine, specifically in the management of acute Clozapine intoxication, as per the study \"The Efficacy of L-Carnitine in the Management of Acute Clozapine Intoxication\" (NCT05632094).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}